Vimian Group enters partnership with biotechnology company Angany Inc. to develop novel vaccines for allergy and atopic dermatitis in companion animals

Vimian Group has signed an agreement to develop new vaccines for allergy and atopic dermatitis together with Angany, a Canadian biotechnology company focused on the development of novel bioparticle-based vaccines.

NewsGuest UserDecember 3, 2021Angany, vaccine, animal health

Angany Announces Vaccine Candidate to Treat Peanut Allergy

Angany Inc., announces today that it has entered into a partnering agreement with Dr. Wayne Shreffler, MD, PhD, Chief, Division of Pediatric Allergy & Immunology and Director of the Food Allergy Center at Massachusetts General Hospital and MassGeneral Hospital for Children, for a comprehensive series of preclinical studies of Angany’s peanut allergy biologic candidate BP/AH-01.

NewsGuest UserNovember 11, 2021Angany, vaccine, Peanut Allergy

Angany (Canada) and Phylloceuticals (USA): two biotechnology innovators team up to accelerate Covid NAbs commercialization

QUEBEC CITY and AUSTIN, Texas, March 24, 2021 /CNW Telbec/ - Dr Louis-Philippe Vézina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the two companies will team up to accelerate the development of a preventive and curative product based on neutralizing monoclonal antibodies (NAbs) against SARS CoV-02 and its variants.